Epidemiology of Micro- and Macrovascular Complications of Type 2 Diabetes in Korea by Kim, Jung Hee et al.
D I A B E T E S  &  M E T A B O L I S M   J O U R N A L
This is an Open Access article distributed under the terms of the Creative Commons At-
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Copyright © 2011 Korean Diabetes Association  http://e-dmj.org
Diabetes Metab J 2011;35:571-577
Epidemiology of Micro- and Macrovascular 
Complications of Type 2 Diabetes in Korea
Jung Hee Kim
1,2, Dae Jung Kim
3, Hak Chul Jang
1,2, Sung Hee Choi
1,2
1Department of Internal Medicine, Seoul National University College of Medicine, Seoul, 
2Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, 
3Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea
The prevalence of diabetes in Korea has increased six- to sevenfold over the past 40 years with its complications becoming major 
causes of morbidity and mortality. The rate of death among patients with diabetes is about twice as high as that among persons 
without diabetes and the most common cause of death is cardiovascular disease (30.6%). Despite the seriousness of diabetic com-
plications, 30 to 70% of patients receive inadequate care, and only 40% of treated diabetic patients achieve the optimal control 
with HbA1c level <7% in Korea. In 2006, over 30 to 40% of patients with diabetes have microvascular complications and around 
10% of them have macrovascular complications from our national data. Despite there are some debates about intensive glycemic 
control resulting in the deterioration of macrovascular complication, multifactorial treatment approaches including proper gly-
cemic control are important to prevent diabetic complications. There have been needs for finding proper biomarkers for predict-
ing diabetic complications properly but we still need more longitudinal studies to find this correlation with causal relationship. 
In this article, we wanted to review the recent status of micro- and macrovascular complications of type 2 diabetes in Korea from 
integration of many epidemiologic studies. 
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INTRODUCTION
The prevalence of diabetes in Korea has increased six- to sev-
enfold from 1.5 to 9.9% over the past 40 years [1,2]. The num-
ber of people with diabetes worldwide is expected to increase 
11.4% from 366 million in 2011 to 552 million by 2030, affect-
ing one in 10 adults [3]. The same trend is expected in Korea. 
This global increase in the prevalence of diabetes will inevita-
bly lead to increases in the prevalence of diabetic microvascu-
lar and macrovascular diseases, and consequently, significant-
ly increased health care expenditure [4].
  In Korea, type 2 diabetic patients without complications 
spend about 1,184,563 won annually on health care. Diabetic 
patients with microvascular disease spend up to 4.7 times as 
much, patients with macrovascular disease up to 10.7 times as 
much, and patients with both complications 8.8 times as much 
as those with no complications. The medical cost of diabetes 
mellitus covered by the national health insurance corporation 
is 3.2 trillion won and accounted for 19.2% of all medical costs 
[5].
  Diabetes and its complications have become major causes 
of morbidity and mortality in Korea [6]. Although diabetes-
related mortality has decreased recently from 25.1 per 100,000 
persons in 2002 to 19.6 per 100,000 persons in 2009, diabetes 
is still the fifth-leading cause of death in Korea [6]. The rate of 
death among patients with diabetes is about twice as high as 
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that among persons without diabetes [7]. The most common 
cause of death is cardiovascular disease (30.6%), followed by 
infectious disease (25.3%), cancer (21.9%), congestive heart 
failure (7.1%), renal disease (4.7%), liver disease (2.7%), and 
diabetes itself (1.9%) [2].
  Despite the seriousness of diabetic complications, 30% to 
70% of patients receive inadequate care [8], and only 40% of 
treated diabetic patients achieve the optimal control, defined 
as an HbA1c level <7% [8,9]. The serious outcomes from dia-
betic complications and inadequate glucose control in diabetic 
patients prompt the need for more aggressive efforts to pro-
vide optimal metabolic control.
COMPLICATIONS OF DIABETES MELLITUS
Type 2 diabetes mellitus is associated with a high rate of com-
plications related to cardiovascular disease and diabetic ne-
phropathy, retinopathy, and neuropathy. In 2006, 30.3%, 38.3%, 
and 44.6% of patients were found to have microvascular com-
plications such as microalbuminuria, retinopathy, and neurop-
athy, respectively from Korean nationwide survey. The preva-
lence of macrovascular complications including coronary ar-
tery disease, cerebrovascular disease, and peripheral artery 
disease was 8.7%, 6.7%, and 3.0%, respectively [9]. The preva-
lence of diabetic foot was 4.4%, and 44.8% of patients with an 
amputated foot had diabetes mellitus [8,10]. The prevalence of 
macrovascular complications seems underestimated in these 
data. In a study of 343 patients with diabetes mellitus, the 
prevalence of cardiovascular complication was 23.6% [11], and 
in another study of 406 patients with diabetes, extracranial in-
ternal carotid artery stenosis ≥40% was detected in 5.2% of 
the patients [12]. In addition, the prevalence of macrovascular 
complication was 10.8% from recent The Korean National Di-
abetes Program (KNDP) data [13] and there is reference from 
2005 Korea National Health and Nutrition Examination Sur-
vey (KNHANES) data in Table 1.
MICROVASCULAR COMPLICATIONS
The role of hyperglycemia in the development of microvascu-
lar complications of diabetes, such as nephropathy, retinopa-
thy, and neuropathy, is well documented. The incidence of mi-
crovascular complications begins to increase at an HbA1c lev-
el >7.0% and increases by 30% to 40% per 1% increase in 
HbA1c level from over 8,000 patients (Fig. 1). Microvascular 
complications are closely related to age, duration of diabetes, 
and glycemic control, and this relationship is stronger than 
that with macrovascular complications [9].
  Diabetic retinopathy is the most common microvascular 
complication of diabetes mellitus, and its prevalence is strong-
ly related to the duration of diabetes. It is the most frequent 
cause of new cases of blindness among adults aged 20 to 74 
years. In Ansung cohort study (prospective, rural, community 
cohort in Korea), the prevalence of any diabetic retinopathy 
was 2.9% and the proper cutoff of HbA1C value for detecting 
any diabetic retinopathy was 6.6% (unpublished data).
Table 1. Prevalence of type 2 diabetes-related complications in 
the KNHANES 2005 population  
Variable Male 
(n=11,726)
Female 
(n=13,489)
Total 
(n=25,215)
Hypertension 1,666 (14.2) 2,100 (15.6) 3,766 (14.9)
Dyslipidemia 396 (3.4) 405 (3.0) 801 (3.2)
Cerebrovascular 
disease 
238 (2.0) 236 (1.8) 474 (1.9)
MI 84 (0.7) 75 (0.6) 159 (0.6)
Angina 133 (1.1) 230 (1.8) 363 (1.4)
Cataract  469 (4.0) 915 (6.8) 1,384 (5.5)
Glaucoma 64 (0.5) 107 (0.8) 171 (0.7)
Values are presented as number (%). Statistically significant between 
males and females by the chi-square test (P<0.05).
KNHANES, Korea National Health and Nutrition Examination Sur-
vey; MI, myocardial infarction (From Rhee SY, et al. Diabetes Metab 
J 2011;35:504-12) [13].
Fig. 1. Odds ratios of diabetic microvascular complications 
according to the glycemic control status (HbA1c) (From Kim 
DJ. Diabetes Metab J 2011;35:303-8) [1].
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  Diabetic nephropathy is characterized by albuminuria 
(≥300 mg/day) and a reduced glomerular filtration rate. It is 
often present at the time of the diagnosis of diabetes after the 
kidney has been exposed to chronic hyperglycemia during the 
prediabetic phase. Patients with microalbuminuria who prog-
ress to macroalbuminuria (300 mg/24 hr) are likely to progress 
to end-stage renal disease (ESRD) [14]. Diabetes is a major 
cause of chronic kidney disease (CKD) and is recognized as 
the most common cause of ESRD in the USA and Korea. About 
40% of United States adults with diagnosed or undiagnosed 
diabetes had some degree of CKD in the 1999 to 2006 Nation-
al Health and Nutrition Examination Survey [15]. In Korea, 
56.7% of CKD patients and 70.5% of ESRD patients has diabe-
tes [8]
  The prevalence of peripheral neuropathy has been estimat-
ed at 40.0% to 44.6% [9,10]. At present, there is no specific 
treatment for the underlying nerve damage other than to im-
prove glycemic control, which may slow the progression mod-
estly. Glycemic control reduces microvascular complication 
outcomes but cannot reverse neuronal loss [16].
MACROVASCULAR COMPLICATIONS
Type 2 diabetes increases the risk of coronary heart disease by 
two- to fourfold [17]. The case fatality rate after myocardial in-
farction is higher in patients with diabetes than in patients 
without diabetes [18]. The association between diabetes and 
coronary heart disease is likely to become more important for 
two reasons. First, the incidence of type 2 diabetes is increas-
ing among both high-risk and low-risk populations. Second, 
although the rate of death caused by coronary heart disease in 
the overall population has declined markedly over the past 35 
years, this has not been the case among persons with diabetes 
[7].
  Cardiovascular disease is the major cause of morbidity and 
mortality for individuals with diabetes and is the largest con-
tributor to the direct and indirect costs of diabetes. Older age, 
high blood pressure, and smoking history are major risk fac-
tors for the development of macrovascular complications. A 
smoking history in males can be both a risk factor and a pre-
dictive factor for earlier development of macrovascular com-
plications in Korean patients with type 2 diabetes [19].
  Microvascular complications of diabetes increase the risk of 
cardiovascular events in diabetic patients. Although diabetic 
retinopathy is not associated with the presence of atheroscle-
rotic plaque, it is associated with increased carotid intima–
media thickness, and the increase in intima–media thickness 
is associated with the presence of plaque, which predisposes 
patients to cardiovascular disease. Microalbuminuria and a 
low glomerular filtration rate (<60 mL/min/1.73 m
2) increase 
the risk of major cardiovascular events and death [20,21]. Dia-
betic polyneuropathy was also independently associated with 
a high prevalence of cardiovascular disease in type 2 diabetic 
patients [22]. These data imply that the microvascular compli-
cations of diabetes are related indirectly to the macrovascular 
complications of diabetes, similar in Korea [23].
THE EFFECT OF GLYCEMIC CONTROL ON 
DIABETIC COMPLICATIONS
Intensive glycemic control has been suggested as an effective 
treatment for reducing the burden of cardiovascular disease 
and microvascular complications in people with diabetes. The 
United Kingdom Prospective Diabetes Study and the Kuma-
moto study showed that early intensive glycemic control can 
delay the onset and progression of diabetic retinopathy, ne-
phropathy, and neuropathy compared with conventional treat-
ment [21,24-26]. Intensive glucose control involving gliclazide 
(modified release) and other drugs as required lowered the 
HbA1c value to 6.5% and reduced by 10% the relative risk for 
the combined outcome of major macrovascular and microvas-
cular events, primarily because of a 21% reduction in incidence 
of nephropathy [27]. In addition, the legacy effect was observed 
after 10 years of trial in the rate of microvascular complication 
and myocardial infarction [28]. In the Steno-2 study, the inten-
sive therapy group had a 46% lower risk for all-cause mortality 
and a 57% lower risk of death from cardiovascular causes. One 
patient in the intensive therapy group progressed to ESRD 
compared with 6 patients in the conventional therapy group, 
and fewer patients in the intensive therapy group required ret-
inal laser therapy [29].
  Although there are many benefits of intensive glucose-low-
ering treatment for preventing macrovascular and microvas-
cular events, it remains uncertain whether these benefits out-
weigh the risks. Intensive blood glucose control decreases the 
risk of developing microvascular complications but not mac-
rovascular disease in patients with type 2 diabetes. In the Ac-
tion to Control Cardiovascular Risk in Diabetes (ACCORD) 
study, an intensive glucose-lowering regimen reduced rate of 
5-year nonfatal myocardial infarctions but was associated with 574
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a 22% increase in mortality [30,31]. A recent meta-analysis 
found that intensive glucose-lowering treatment has limited 
effect on the rates of all-cause mortality and death from car-
diovascular causes. The data are conflicting: a 9% reduction to 
a 19% increase in all-cause mortality and a 14% reduction to a 
43% increase in cardiovascular death rates. The harm associat-
ed with severe hypoglycemia might counterbalance the poten-
tial benefit of intensive glucose-lowering treatment [32]. The 
microvascular benefits of intensive therapy should be weighed 
against the increase in total and cardiovascular disease-related 
mortality, weight gain, and high risk of severe hypoglycemia 
[16]. 
  However, multifactorial approaches in high risk patients 
with diabetes, such as tight glucose regulation and the use of 
anti-hypertensive medication, aspirin, and lipid-lowering 
agents, have been shown to reduce the risk of nonfatal cardio-
vascular disease among patients with type 2 diabetes mellitus 
and microalbuminuria. In high risk patients with type 2 dia-
betes, intensive treatment approaches with multiple drug 
combinations and behavior modification had sustained bene-
ficial effects with respect to vascular complications and on 
rates of death from any cause and from cardiovascular causes 
[29].
ADIPOKINE AND DIABETIC 
COMPLICATIONS: RISK FACTORS FOR 
DIABETES
Several adipokines are implicated in the metabolic syndrome, 
coronary heart disease, and insulin resistance. We want to dis-
cuss some adipokines, which showed correlation with diabetes 
and metabolic syndrome in Korea. Lipocalin family proteins, 
including adipocyte fatty acid-binding protein (A-FABP), li-
pocalin-2, and retinol-binding protein 4 (RBP4), have been 
identified recently as adipokines associated with obesity, type 
2 diabetes, and the metabolic syndrome. Serum A-FABP is as-
sociated with glucose dysregulation, and its level predicts the 
development of type 2 diabetes and the development of the 
metabolic syndrome independently of adiposity and insulin 
resistance [33,34]. Serum A-FABP level is independently asso-
ciated with carotid atherosclerosis [35]. Serum lipocalin-2 lev-
el is significantly elevated in patients with coronary heart dis-
ease and is independently associated with coronary heart dis-
ease. These findings suggest that serum lipocalin-2 levels may 
be useful for assessing coronary heart disease risk [36]. Plasma 
RBP4 concentration is elevated in persons with impaired glu-
cose tolerance and type 2 diabetes [37]. High RBP4 and low 
plasma adiponectin concentrations are associated with the se-
verity of glucose intolerance in women with previous gesta-
tional diabetes mellitus [38].
  A low circulating vaspin level correlates with a high fitness 
level, whereas physical training in untrained individuals in-
creases vaspin serum concentration [39]. Vaspin is also corre-
lated with metabolic syndrome in men and coronary artery 
stenosis in women [40]. However, another study reported that 
circulating visfatin may not be a useful clinical biomarker of 
metabolic status [41].
  A relationship between chemerin levels, cardiometabolic 
parameters, and degree of coronary stenosis has been reported 
in Korean patients with coronary artery disease [42].
  Serum osteocalcin, an osteoblast-specific protein, has sev-
eral hormonal features and is secreted into the general circula-
tion by osteoblastic cells. Serum osteocalcin and osteoprote-
gerin levels are associated with glucose metabolism and ath-
erosclerosis parameters in people with type 2 diabetes mellitus 
[43,44]. 
  Even though there are many studies about adipokines and 
metabolic diseases, we need large number, prospective studies 
to see the causality between the candidate adipokines and dia-
betic complications more clearly.
CONCLUSION
The increasing prevalence of diabetes mellitus and its related 
complications have contributed to a substantial increase in 
morbidity and mortality in Korea. However, the proportion of 
patients with type 2 diabetes achieving adequate glucose con-
trol is relatively low. Multifactorial treatment approaches that 
target hypertension, dyslipidemia, and microalbuminuria, and 
that provide intensive glycemic control are urgently needed to 
control diabetes. These comprehensive and integrated health 
interventions will lead to further improvement in the manage-
ment of diabetes.
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